Clinical Trials
6 trialsNCT05551507 2026-05-04
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06710288 2025-10-20
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
ImmunityBio, Inc.
Phase 2 Recruiting
NCT04374630 2025-09-10
PROFECTA-II
Laekna Limited
Phase 2 Completed
NCT04678102 2023-06-26
CREATIVE
Seoul National University Hospital
Phase 1 Unknown
NCT05736952 2023-05-11
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Withdrawn
NCT04376073 2020-11-25
ANNIE
Sun Yat-sen University
Phase 2 Unknown